1. Introduction {#s0005}
===============

In 2016, an estimated 216 million cases of malaria worldwide led to more than 445,000 deaths, mostly among children in sub-Saharan Africa ([@bib35]). Effective management for uncomplicated cases of *Plasmodium falciparum* malaria, the species causing the majority of fatal infections, requires confirmed diagnosis and, if positive, treatment with artemisinin combination therapy (ACT), ideally prescribed and dispensed from a qualified provider. However, access to appropriate diagnosis and treatment is still inadequate, resulting in a large treatment gap where many cases are managed sub-optimally or even go untreated.

To illustrate, although nearly a decade has passed since the World Health Organization (WHO) updated its guidelines for treating uncomplicated falciparum malaria to recommend confirmed diagnosis and ACT, it is estimated that among febrile children in sub-Saharan Africa for whom care was sought, only 30% received a diagnostic test either by microscopy or rapid diagnostic test (RDT) in 2014-16 ([@bib35]). Moreover, many of those with malaria do not receive ACT. For example, studies in Tanzania found that among cases positive for malaria by reference blood slide, just over half (50.2%) received ACT in government facilities and less than a third of those who sought care from private drug stores ([@bib5], [@bib6]). Many more were not brought for care or received older non-artemisinin therapies (nATs), such as sulphadoxine-pyrimethamine and chloroquine. Widespread parasite resistance has rendered nATs less effective in many endemic regions of sub-Saharan Africa ([@bib19], [@bib28]).

Poor coverage of effective treatment persists despite considerable investment by Ministries of Health and their partners in a range of strategies to address the issue. These interventions typically aim to reduce critical access barriers in various ways. For example, efforts have been made to increase ACT and RDT availability at government facilities, dispense them free of charge from public sector outlets, train community health workers and private retailers (i.e. pharmacies and drug stores) to conduct diagnostic testing and dispense appropriate treatment, curtail the retailing of non-ACT, and lower private sector ACT prices through subsidies ([@bib7], [@bib11], [@bib22], [@bib34]). The most notable of these subsidy programmes was the Affordable Medicines Facility--malaria (AMFm), which was piloted in several endemic countries, including Nigeria and Uganda, from 2010--12 ([@bib32]). The AMFm was a multi-national subsidy programme for ACTs implemented at a national scale in 7 African countries, funded by the Global Fund to Fight HIV, TB and Malaria. It aimed to increase the appropriate use of quality-assured ACTs and decrease the use of other antimalarials, through a combination of ACT subsidies and supporting interventions such as recommended retail prices and communications campaigns. However, despite all these efforts, the size of the treatment gap indicates that much more still needs to be done to improve malaria case management.

Within the international public health community, it is now widely acknowledged that access to health care is a multi-dimensional concept based on the interaction or 'degree of fit' or 'alignment' between health care systems and individual, household, and community needs, which may either empower or hinder an individual's use of appropriate health care ([@bib12], [@bib15]). One such definition developed by McIntyre and colleagues categorises the many factors that determine access into three dimensions: availability or physical access, affordability or financial access, and acceptability or cultural access ([@bib15]). In addition, it has been argued that efforts to understand health care use must account for the broader range of treatment options that an individual might engage with, beyond official medical sources ([@bib14]). This is of particular relevance for malaria treatment, which is known to involve a diverse array of providers ranging from public, private and faith-based health care facilities, to retail pharmacies, drug stores, and general retailers ([@bib13]).

Efforts to define health care access have tended to focus on its conceptualisation, without much attention to the application of the concept or its measurement ([@bib15]). Indeed, this is evident in many of the common indicators used to measure access. For example, access indicators derived from household data such as Demographic and Health Surveys (DHS), Multiple Indicator Cluster Surveys and Malaria Indicator Surveys ([@bib9], [@bib23], [@bib33]), may provide information on distance or travel time to the chosen health care provider, the type of treatment obtained and its price. However, these indicators do not give information on the broader range of provider options available to that individual or to individuals not seeking treatment, or on the range and price of the alternative treatments that providers offer. In particular, these data do not reveal whether a household has at least one provider in their area with the required health products and services. In the case of malaria, such information is critical to understand the choice not to seek care or to obtain sub-optimal treatment.

On the other hand, health care facility or provider surveys and administrative datasets may be able to provide comprehensive descriptions of the supply side. For example, the Service Provision Assessment surveys offered by the DHS collect data on the specific health services offered by facility type and whether these facilities have the necessary infrastructure, resources and support systems available ([@bib9]). However, such average data on provider readiness cannot reveal what a given household's access to these services actually is, especially as the better performing facilities may be clustered geographically, and such assessments rarely include all provider types. Such indicators also cannot also account for how well accessible health care products and services align with actual need.

Therefore, measures of access that combine both household and provider data to characterise all the treatment options available to an index household could substantially improve our understanding of health care access. This paper describes a novel method to develop such measures by combining supply- and demand-side survey data from the ACTwatch project to produce nationally representative indicators of access to care for malaria. We demonstrate the utility of this approach by estimating a select range of physical and financial access indicators that characterise the malaria treatment options available to households with a febrile child in Benin, Nigeria, Uganda and Zambia, and use these to describe how access has changed over time.

2. Methods {#s0010}
==========

2.1. Data and source {#s0015}
--------------------

The ACTwatch project was designed to generate nationally representative information on antimalarial markets through linked cross-sectional surveys of households, treatment sources and private sector distribution chains in selected endemic countries ([@bib24]). Participating countries were chosen to represent a diverse range of contexts considering variation in malaria burden, the nature of pharmaceutical regulation (e.g. high vs. low regulatory capacity; francophone vs. anglophone settings), public sector coverage, and domestic antimalarial manufacturing capacity.

This study uses household and treatment source data from two survey rounds conducted in Benin, Nigeria, Uganda and Zambia. We selected two countries which had received the AMFm antimalarial subsidy (Nigeria and Uganda) and two which had not (Benin and Zambia). The first round (baseline) was conducted in 2009-10 (pre-AMFm), and the second round (endline) in 2011-12 (during AMFm). In each country and during each round, household and treatment source surveys were conducted contemporaneously using a common multi-staged clustered sampling design. Briefly, national samples of households and treatment sources were drawn from the same primary sampling units (PSUs), within which every treatment source that had recently stocked an antimalarial (i.e. within the preceding three months) was eligible for inclusion. Treatment sources were identified using a census approach and included public and not-for-profit health facilities, private (for-profit) health facilities, retail pharmacies, drug stores (apart from in Benin; also known as Patent Proprietary Medicine Vendors, or PPMVs, in Nigeria), and general retailers, such as grocery stores, kiosks and market stalls ([@bib18]). As public health facilities and pharmacies are important, but relatively uncommon sources of antimalarials, these provider types were over-sampled by including such providers in the larger administrative area from which a given PSU was selected. For example, if the PSU was defined as the sub-district, all public health facilities and pharmacies in the whole district within which the sub-district was located were sampled.

Households containing a recently febrile child were randomly selected from three secondary sampling units drawn within each PSU surveyed. The household surveys collected demand-side information on the treatment choices made for febrile children, and on personal and household characteristics, while the treatment source surveys collected supply-side information on the availability and price of all antimalarials and all malaria diagnostics, and other provider characteristics related to staffing, storage conditions, knowledge, etc. Geographic coordinates were also collected from all surveyed households and treatment sources. [Table 1](#t0005){ref-type="table"} provides details of the household and treatment source samples in each country (with breakdown by rural/urban strata in [Appendix](#s0085){ref-type="sec"} [Table A](#t0015){ref-type="table"}, [Table B](#t0020){ref-type="table"}); sampling and survey procedures are described elsewhere ([@bib13], [@bib18], [@bib24]).Table 1Characteristics of the household and treatment source samples by survey round and country.Table 1**BeninNigeriaUgandaZambiaSurvey round**12121212**Survey Date**Apr-Jul 2009Apr-Jul 2011Aug-Nov 2009Oct 2011-Jul 2012Mar-Apr 2009Nov 2011-May 2012Apr-Jul 2009Mar-Sep 2011**Number of strata**11622222Total clusters19191107638443838**Total households screened**2312327546167863206350672218\*Number of households with a febrile child under 5 years874904280213101523182616931205Number of households with multiple febrile cases63117469216266403188132**Total febrile children under 5 years surveyed**9271015327415511753227418861341Number of cases receiving an antimalarial37853310605658991177709555Number of cases for whom no initial treatment was sought16131129267861172109Number of cases initially treated at home40955610467326151376455317Number of cases seeking care from multiple external sources36102302162143309119188**Number of outlets screened**1670273854567939526716 20733785436Number of ineligible outlets609134832466372398912 92229174565Number of outlets surveyed106113902196156212783227461861Number of outlets stocking ACT29958811689476152697240474Number of outlets stocking nAT82811192042143311592920424742Number of outlets stocking oral AMT46510855511671268                  **Number of antimalarial tablets inventoried**Number of ACTs2023400946143254116287707081446Number of nATs1730222065654289227550837271164Number of oral AMTs59516236972371208[^1]

2.2. Producing the access dataset and indicators {#s0020}
------------------------------------------------

In each country, we merged household and treatment source data for each survey round to create the access datasets. For each surveyed household with a recently febrile child, a treatment choice set was defined by forming pairwise links between each household and all treatment sources surveyed that lay within a 5 km radius, reflecting likely willingness to travel for antimalarial providers, as noted in the literature ([@bib16], [@bib17], [@bib31]). Straight-line distances between households and paired treatment sources were calculated using the *geodist* package in Stata 13 ([@bib27]), and sources located more than 5 km away were removed from that household's treatment choice set. A 5 km radius was chosen to approximate a one-hour walking distance, which has been used previously to denote reasonable geographic access in developing country contexts ([@bib25], [@bib26], [@bib29]). Defining treatment choice sets in this way potentially introduces a measurement bias when surveyed households are located close to the border of the PSU. This would result in underestimation of access because treatment options close to the household, but outside the PSU border, would be excluded from the choice set. Such bias is less for public health facilities and pharmacies as these were oversampled from a larger area surrounding the PSU; however, statistical comparisons between these and other provider types are not appropriate given the difference in sampling approaches.

Using the merged household and treatment source data we characterise health care access from the perspective of households. In this paper, we present the following nationally representative indicators by urban and rural location, and by survey round, for an access area defined by a 5 km radius around households: % households with access to any treatment source stocking any antimalarial; % households with access to any treatment source stocking ACT; % households with access to ACT by type of treatment source; % households with access to any treatment source offering malaria diagnostic services; % households with access to any treatment source staffed by a qualified health professional (i.e. medical doctor, nurse, midwife, pharmacist); % households with access to any treatment source with ACT, offering diagnostic services and staffed by a qualified health professional; median number of treatment sources stocking ACT; and median price for ACT, nAT and oral artemisinin monotherapy (AMT) tablets.

2.3. Statistical analysis {#s0025}
-------------------------

Indicator estimates were adjusted using inverse-probability sampling weights to account for differences in the household probability of being selected in those countries where samples were stratified. Standard error estimation accounted for clustering within primary and secondary sampling units. Thus, estimates are conservative and reduce the likelihood of incorrectly rejecting the null hypothesis.

Percentage-based estimates are presented with 95% confidence intervals (CI), and differences in percentages over time are tested against the null hypothesis of no change. Prices for ACT tablets, the most common dosage form used for treatment, are presented in adult equivalent treatment doses (AETDs), a standardised unit that allows for comparison of products with different treatment regimens. Prices were adjusted to a 2010 base using the World Bank annual consumer price index values, and converted to US dollars (USD) using the average weekly exchange rate in 2010 ([@bib18], [@bib32]). Price-based indicators are estimated as medians with interquartile range (IQR), and differences over time are examined using the Wilcoxon rank-sum test. Analyses were conducted in Stata 13 and R version 3.0.2 ([@bib27], [@bib30]).

3. Results {#s0030}
==========

3.1. Physical access to ACT and other antimalarials {#s0035}
---------------------------------------------------

Differences in physical access to ACTs and other antimalarials were observed across urban and rural areas and over time. In urban areas, ACTs were accessible to the majority of households. In all four countries both at baseline and endline, more than 85% of urban households had access to at least one source of ACTs within a 5 km radius ([Fig. 1](#f0005){ref-type="fig"}). Physical access to ACTs in rural areas was lower than in urban areas; however, in Benin, Nigeria and Uganda, household access to ACTs in rural areas improved over time. For example, the percentage of rural households in Benin with access to at least one source of ACTs within 5 km increased from 51% to 76% (p-value: 0.023) between surveys. In Uganda, the urban-rural ACT access gap had largely been eliminated by 2012 where over 95% of households in both urban and rural areas had access to at least one source of ACT within 5 km, whereas in Zambia, household access did not improve in rural areas between baseline and endline. In addition, no notable changes in physical access to any antimalarial were observed over time in any of the study countries. As such, the significant improvements in ACT access noted in rural areas of Benin, Nigeria and Uganda may indicate that over time existing sources previously stocking only non-ACTs have begun to stock ACT as well.Fig. 1Percentage and 95% confidence interval of households with access to ACT and any antimalarial within 5 km by urban-rural location and over time, with 95% confidence interval (For differences in percentages over time: \* p≤0.1, \*\* p≤0.05, \*\*\* p≤0.001).Fig. 1

Our analysis was based on repeated cross-sectional surveys rather than panel data (i.e. different PSUs were selected in each round). While each round was designed to be nationally representative, it is possible that the selection of outliers in terms of PSU characteristics in one round could have influenced estimates of change over time. Inspection of sample characteristics disaggregated by urban/rural strata ([Appendix](#s0085){ref-type="sec"} [Table A](#t0015){ref-type="table"}, [Table B](#t0020){ref-type="table"}) shows that there were no substantial differences in average outlet numbers per PSU in all cases except Uganda, where at endline the urban PSUs selected had a higher average number of antimalarial outlets than those selected at baseline ([Appendix](#s0085){ref-type="sec"} [Table A](#t0015){ref-type="table"}, [Table B](#t0020){ref-type="table"}). However, this does not affect the patterns described above as the only notable improvements in access in Uganda were seen in rural areas.

3.2. Physical access to ACT by treatment source {#s0040}
-----------------------------------------------

Examining changes in the composition of treatment sources within the vicinity of households provides further information on factors driving the improvements in physical access to ACTs described above ([Fig. 2](#f0010){ref-type="fig"}). During both survey rounds, many urban households had access to a variety of ACT sources within a 5 km radius, including public and not-for-profit facilities, private for-profit facilities and retail pharmacies ([Fig. 2](#f0010){ref-type="fig"}a). Nearly all urban households in Nigeria had access to ACTs via drug stores, which were also common options for households in Uganda and Zambia. In contrast, households in rural areas had fewer options to access ACTs ([Fig. 2](#f0010){ref-type="fig"}b). Public and not-for-profit health facilities provided access to ACTs to over half of rural households only in Benin and Uganda, but were still the most common option in rural Zambia. Drug stores were the dominant source of ACT accessible to rural households in Nigeria and for a considerable proportion of households in Uganda.Fig. 2Percentage and 95% confidence interval of (a) urban and (b) rural households with access to ACT within 5 km by treatment source and over time, with 95% confidence interval (For differences in percentages over time within sources: \* p≤0.1, \*\* p≤0.05, \*\*\* p≤0.001. Notes: Drug stores were not surveyed in Benin as they are not a common provider type; comparisons across types of treatment source may not be appropriate as public facilities and pharmacies were oversampled in ACTwatch surveys).Fig. 2

Over time, there is some evidence that the proportion of urban households with access to ACTs increased through private for-profit facilities in Uganda (77% to 96%, p-value: 0.011); drug stores in Nigeria (89% to 96%, p-value: 0.058); and unlicensed general retailers in Benin (32% to 83%, p-value: 0.014), Uganda (0% to 16%, p-value: 0.064) and Zambia (0% to 36%, p-value: 0.001). In the four countries, there were no significant increases in household access to ACTs through public or not-for-profit providers observed in urban areas; however, in rural areas of Uganda, the proportion of households with access to ACT through these providers increased from 56% to 85% (p-value: \<0.001). There is also evidence that rural household access improved through private health facilities in Uganda (15% to 52%, p-value: \<0.001); drug stores in Nigeria (46% to 70%, p-value: 0.020), Uganda (24% to 92%, p-value: \<0.001) and Zambia (0% to 12%, p-value: 0.029); and unlicensed general retailers in Benin (11% to 46%, p-value: 0.015) and Nigeria (1% to 8%, p-value: 0.094).

In [Table 2](#t0010){ref-type="table"}, we present figures for the median number of treatment sources stocking ACT within 5 km of households over time. In Uganda, the number of ACT providers that a typical household could choose from increased eightfold between 2009-10 and 2011-12, from a median of 10 to 80 providers for urban households, and from a median of 1 to 8 providers for rural households. More modest increases were observed for rural households in Benin and Nigeria, where the median rose from 1 in 2009-10 to 2 by 2011-12. There were no notable changes in rural Zambia. These households had access to a median of 0 treatment sources stocking ACT within 5 km in both survey rounds.Table 2Median number of treatment sources stocking ACTs within 5 km of urban and rural households over time, with interquartile range (IQR).Table 2**UrbanRuralMedianIQRp-valueMedianIQRp-valueBenin**NBaseline=269, Endline=241Baseline=595, Endline=659Baseline5(3--28)0.2111(0--3)0.086Endline20(9--55)2(1--4)        **Nigeria**NBaseline=995, Endline=726Baseline=1739, Endline=580Baseline10(6--22)0.4391(0--3)0.010Endline13(7--29)2(0--7)        **Uganda**NBaseline=154, Endline=908Baseline=1308, Endline=903Baseline10(9--13)\<0.0011(0--3)\<0.001Endline80(41--154)8(5--13)        **Zambia**NBaseline=848, Endline=471Baseline=841, Endline=600Baseline11(4--17)0.3340(0--1)0.596Endline7(2--16)0(0--1)

3.3. Physical access to malaria diagnostic services and qualified health professionals {#s0045}
--------------------------------------------------------------------------------------

Urban households had ready access to health professionals and malaria diagnostic services ([Fig. 3](#f0015){ref-type="fig"}a). More than 90% of these households in all four study countries had at least one antimalarial source staffed by a qualified health professional within 5 km, and similar proportions of urban households also had at least one antimalarial source that offered malaria diagnostic services within 5 km in all countries except Nigeria. In rural areas, households in Uganda had a comparable level of access to health professionals as in urban areas, but access to health professionals was lower in rural areas in the remaining countries ([Fig. 3](#f0015){ref-type="fig"}b). Household access to diagnostic services in rural areas was poor at just over 50% of households in Benin and over 40% in Zambia. Rural access to diagnostics in Nigeria increased from 12% to 24% of households between surveys (though this change was not statistically significant); and increased from 52% to 89% of rural households in Uganda (p-value: \<0.001).Fig. 3Percentage and 95% confidence interval of (a) urban and (b) rural households with access to antimalarial providers with malaria diagnostics; health professionals; and ACT, diagnostics and health professionals within 5 km (For differences in percentages over time within sources: \* p≤0.1, \*\* p≤0.05, \*\*\* p≤0.001. Note: Drug stores were not surveyed in Benin as they are not a common provider type).Fig. 3

[Fig. 3](#f0015){ref-type="fig"} also illustrates changes in household access within 5 km to any treatment sources stocking both ACT and malaria diagnostics, and staffed by a qualified health professional - the three core elements of malaria case management. More than half of urban households in all four countries had access to at least one of these providers in 2009-10 and 2011-12, and more than 90% of urban households in Uganda and Zambia ([Fig. 3](#f0015){ref-type="fig"}a). This access was much lower for rural households ([Fig. 3](#f0015){ref-type="fig"}b). Less than a quarter of rural households in Benin and Nigeria, and approximately 40% in rural Zambia had access to any treatment source stocking both ACT and malaria diagnostics, and staffed by a qualified health professional in 2009-10 and 2011-12. Over time improved access to these providers was observed only in rural Uganda, where the proportion of households with such access increased from 38% in 2009-10 to 86% by 2011-12 (p\<0.001).

3.4. Price of antimalarials accessible to households {#s0050}
----------------------------------------------------

Because public and not-for-profit health facilities typically dispense ACT free of charge or at heavily subsidised prices (as in Benin), low-cost ACT was accessible to a large majority of urban households in the study countries with access via these treatment sources ([Fig. 2](#f0010){ref-type="fig"}a). In contrast, fewer rural households had ready access to affordable ACTs via public and not-for-profit health facilities ([Fig. 2](#f0010){ref-type="fig"}b), which could result in delayed treatment or seeking care from more expensive private for-profit providers. [Fig. 4](#f0020){ref-type="fig"} illustrates the median price of ACT (per AETD, 2010 USD) available from private for-profit providers only among those households with access to them by country, urban-rural location and over time.Fig. 4Median price and interquartile range of private sector ACT tablets (2010 USD) per adult equivalent treatment dose within 5 km of urban and rural households over time (For differences in median over time: \* p≤0.1, \*\* p≤0.05, \*\*\* p≤0.001).Fig. 4

At baseline, the median price of private sector ACT tablets accessible to urban households ranged from 4.94 USD per AETD in Nigeria to 8.33 USD in Zambia, and for rural households from 3.01 USD in Nigeria to 8.44 USD in Benin. In all countries except Benin, prices for ACT tended to be higher in urban than in rural areas.

Over time, the median prices of ACT accessible to households decreased in all areas of the study countries. However, these changes were statistically significant for urban and rural households in Nigeria (rural: from 4.94 to 2.16 USD, p-value: \<0.001; urban: from 3.01 to 1.71 USD, p-value: \<0.001), rural households in Benin (from 8.44 to 2.55 USD, p-value: \<0.001), and urban households in Zambia (from 8.33 to 6.75 USD, p-value: 0.001). No significant changes were observed in Uganda. Median prices for private sector AMT and nAT, and addition details for ACT tablets are presented in [Appendix](#s0085){ref-type="sec"} [Table C](#t0025){ref-type="table"}.

4. Discussion {#s0055}
=============

4.1. Summary of findings and policy implications {#s0060}
------------------------------------------------

By combining data from households with information on the complete range of treatment sources in their vicinities, we have produced a variety of nationally representative indicators that describe malaria treatment access from the household perspective, and how this has changed over time in dynamic, pluralistic health care markets. We characterise two out of the three dimensions of access (i.e. physical and financial), but do not address the acceptability dimension.

Our findings show that by 2011-12, although the urban-rural gap in physical ACT access persisted in Zambia, progress had been made in Benin and Nigeria, and this gap had largely closed in Uganda. The results also demonstrate that the private sector helped reduce this gap in underserved areas. This was seen in Nigeria and Uganda where increased household access was driven largely by increased ACT availability in licensed drug stores, which was in large part due to these countries' participation in the AMFm ACT subsidy programme that explicitly aimed to increase ACT availability and affordability among private retailers ([@bib32]). Although Benin did not participate in AMFm previous research has shown that Benin's private retail sector is heavily dependent on Nigeria for antimalarial supplies ([@bib20]), so that the impact of AMFm was indirectly felt in Benin as well. After the official end of AMFm, ACT subsidies were maintained in Nigeria and Uganda under the Private Sector Co-payment Mechanism, which sustained the improvements in access achieved during the AMFm period ([@bib2]).

However, increasing physical access through private for-profit providers carries potential consequences for the affordability of care. Although we do not measure ability to pay, our data on price are an important component of financial access. To illustrate, access to ACT for rural households in Uganda in 2009-10 was predominantly via public and not-for-profit health facilities where treatment should be dispensed free of charge. The increases in physical access seen by 2011-12 were driven largely through more private for-profit health facilities and drug stores stocking ACT. Although free treatment from public and not-for-profit facilities was still available to rural households in Uganda in 2011-12, individuals may choose to purchase more expensive ACT from private providers because they may be more convenient in terms of proximity, waiting times and opening hours. However, the observed decreases in private sector ACT prices demonstrate the role that interventions, like the AMFm ACT subsidy programme, continue to play in ensuring wide access to more affordable ACTs ([@bib2]). Nonetheless, improving physical access to affordable care in public facilities must remain as a core objective of equitable health system strengthening in these settings as even subsidised ACT will still be out of reach for many.

Results from Benin and rural Zambia also illustrate some less desirable effects of broader private sector involvement, where rising ACT availability among general retailers contributed to the observed increase in household access. In Benin, previous studies have shown that unlicensed and unregulated open-air market stalls selling antimalarials dominate this class of provider ([@bib18]), among whom it would be difficult to ensure the quality of medicines and case management. On the other hand, it could be argued that it is unrealistic to expect most people to seek care through Benin's mainly urban private facilities and pharmacies, and therefore, steps should be taken to increase the quality of alternative treatment sources. Such measures could include introducing a category of regulated medicine dispenser akin to drug stores in other countries, support for market stall vendors who wish to upgrade, and training on malaria case management for drug store operators ([@bib8], [@bib22]).

While our findings show that the ACT access gap is closing, they also illustrate that, apart from in Uganda, much more could be done to improve rural access to the other core elements of appropriate malaria case management - diagnostics and qualified health professionals. By 2011-12, among rural households in Benin, Nigeria and Zambia, less than 70% had access to a treatment source within 5 km staffed by a qualified health professional, and less than half had access to malaria diagnostics. Access to an outlet within 5 km with all three core elements of malaria case management in rural areas was 40% of households in Zambia, 27% in Benin and only 16% in Nigeria. Public and private health facilities continue to be the dominant providers of diagnostic services in endemic countries ([@bib1]). Given the positive impact that engagement with private providers has had on improving access to ACT, careful consideration needs to be given to the role private retailers should play in ensuring that malaria diagnostics, and rapid diagnostic tests in particular, cover the last mile ([@bib34]).

4.2. Methodological insights into measuring health care access {#s0065}
--------------------------------------------------------------

We believe that the methods presented here produce indicators of access that improve upon those previously used, and that they have many useful applications. First, we have demonstrated how examining treatment availability and prices charged from the perspective of households provides more intuitive and meaningful descriptions of access. As described in the introduction, typical access indicators are often limited to demand- or supply-side descriptions, typically averaged over broad strata (e.g. urban/rural), while our indicators provide direct measures of the services obtainable within a reasonable distance from households, thus providing evidence on 'last mile' coverage ([@bib12], [@bib15]).

A further advantage of this approach is that access to health services can be *aligned with actual need*. To do this for our malaria case study, we use information from the ACTwatch household survey on reported fever for a child under the age of 5 years, which other open access resources, such as maps of populations or structures, do not provide. While reported fever in the study countries was widely distributed, this aspect of the approach could be more important for other conditions that are more geographically clustered, such as HIV and tuberculosis.

When such fine-grained descriptions of access are examined over time, these indicators also provide much clearer understanding of whether household access has improved, and the changes driving those improvements. When considered alongside the acceptability dimension of access, this can indicate how such changes may impact treatment utilisation and ultimately, health outcomes. In applying these methods to malaria treatment, we have probed such access changes in Benin, Nigeria and Uganda, and the lack thereof in Zambia. These indicators could then be used as explanatory variables in analysing changes in treatment seeking behaviour. Given this explanatory potential, such indicators could be used to better evaluate the impact of interventions designed to improve access to care.

These particular strengths of our method rely not only on the ability to combine contemporaneous demand- and supply-side data from the same locations, but also on the comprehensiveness of the supply-side data. A number of previous analyses have linked Service Provision Assessment data with DHS household data in novel and interesting ways ([@bib3], [@bib25]). However, Service Provision Assessments focus on public and private facilities only and, therefore, do not provide information on the availability of other treatment options, particularly in the retail sector which is such an important source of malaria treatment. By contrast, the ACTwatch treatment source surveys provide a complete picture of the treatment landscape.

However, conducting simultaneous household and treatment source surveys is logistically challenging and costly. This is particularly the case when including all treatment sources as the presence of less qualified providers and retailers is generally not well-documented, meaning that a detailed census must be conducted. Since the end of the ACTwatch project, such total market surveys of malaria treatment sources are not being conducted, so alternative sources of data would need to be found to produce comprehensive assessments of access to malaria treatment. One option could be to expand Service Provision Assessments to include a census of all provider types in PSUs and collect a broader range of supply-side data in countries where DHS household surveys include the malaria module. The methods in this paper could also be applied using data from ACTwatch's sister project FPwatch, which involves surveys of all family planning providers alongside household surveys ([@bib21]). Conversely, for cases where concurrent, co-located household data are not available, open source maps of populations or structures could be used to locate households and then be merged with supply-side data from sources such as those described above. However, since these open access resource typically do not include information on actual household need for care, this approach would be better suited to measuring access to care for conditions that are more or less evenly distributed within a population.

Our approach of using a 5 km radius around households to define their treatment choice sets represents a fairly simplistic use of geospatial data, and we recognise that more sophisticated methods, such as those that estimate road distance and travel time, could be used to assess physical access ([@bib4], [@bib10]). As described in methods, defining treatment choice sets in this way also risks underestimating access for households located close to the borders of sampled PSUs, although the effect of this bias could be minimised by reducing the radius length used. Other important biases to consider are those typical when using self-reported data. For example, social desirability bias may have led to under-reporting of antimalarial prices and the availability of undesirable treatments by providers (i.e. oral AMT). While a methodological strength of the approach is the full census of treatment sources in PSUs, some providers with the potential to sell antimalarials may have been missed, leading to underestimates of treatment availability.

5. Conclusion {#s0070}
=============

In this paper, we have described an approach to operationalise the physical and financial dimensions of access to health care from the household perspective. Applying these methods to examine access to malaria treatment in four endemic countries, we have also illustrated how this novel approach provides a more useful understanding of access to care in pluralist and varied health care markets. This approach also facilitates an understanding of the drivers of changes in access over time and could lead to better explanations of the performance of complex interventions aiming to improve healthcare access.

Appendix {#s0085}
========

See [Table A](#t0015){ref-type="table"}.Table ACharacteristics of the urban household and treatment source samples by survey round and country.Table A**BeninNigeriaUgandaZambiaSurvey round**12121212**Number of strata**11622222Total clusters6648394181919**Total households screened**75110051835461419128831267\*Number of households with a febrile child under 5 years2722431016730157913849512Number of households with multiple febrile cases3128147112141737339**Total febrile children under 5 years surveyed**29926711608521701103927553Number of cases receiving an antimalarial168124413309107523298166Number of cases for whom no initial treatment was sought13334115179139Number of cases initially treated at home161183436426165683231134Number of cases seeking care from multiple external sources16319695171706070**Number of outlets screened**1058233641675706566791426514328Number of ineligible outlets305119123484635483645523223712Number of outlets surveyed753114518091068831423329607Number of outlets stocking ACT1774611032671351287162301Number of outlets stocking nAT5869421687981821348301528Number of outlets stocking oral AMT414958406261238                  **Number of antimalarial tablets inventoried**Number of ACTs1478364543782445514908455969Number of nATs13411936566830162232545525808Number of oral AMTs5441479532341158

See [Table B](#t0020){ref-type="table"}.Table BCharacteristics of the rural household and treatment source samples by survey round and country.Table B**BeninNigeriaUgandaZambiaSurvey round**12121212**Number of strata**11622222Total clusters1313823734261919**Total households screened**156122702781324918722234953\*Number of households with a febrile child under 5 years60266117865801336913844693Number of households with multiple febrile cases328932210425223011593**Total febrile children under 5 years surveyed**628748211469915831171959788Number of cases receiving an antimalarial210409647256792654411389Number of cases for whom no initial treatment was sought14828951573448170Number of cases initially treated at home248373610306563693224183Number of cases seeking care from multiple external sources20712066712613959118**Number of outlets screened**61845412892233470182937271108Number of ineligible outlets307184898173735066467595853Number of outlets surveyed31127038749411951804132254Number of outlets stocking ACT124137136276580141078173Number of outlets stocking nAT24519935545210771572123214Number of outlets stocking oral AMT61127145141030                  **Number of antimalarial tablets inventoried**Number of ACTs57440823680911113862253477Number of nATs409331897127320522538202356Number of oral AMTs61144165203050

See [Table C](#t0025){ref-type="table"}.Table CMedian price and IQR (2010 USD) of private sector antimalarial tablets within 5 km of households by antimalarial type and over time.Table C**UrbanRuralMedianIQRp-valueNMedianIQRp-valueNBenin**ACT tabletsBaseline8.14(6.26--8.32)0.0772678.44(8.14--9.24)\<0.001168Endline7.53(3.14--7.58)1912.55(1.77--7.55)335                    AMT tabletsBaseline9.83(8.57--10.73)0.0101218.29(8.29--16.52)0.29764Endline7.26(7.26--7.26)165.39(5.39--5.39)55                    nAT tabletsBaseline0.80(0.39--1.03)0.2172670.45(0.26--1.45)0.153408Endline0.90(0.48--2.48)2010.53(0.48--1.91)415**Nigeria**                    ACT tabletsBaseline4.94(3.50--5.27)\<0.0018923.01(2.64--3.77)\<0.001737Endline2.16(1.35--2.32)7021.71(1.35--2.16)415                    AMT tabletsBaseline3.61(3.01--3.61)\<0.0018993.31(2.71--3.77)0.003756Endline2.43(2.16--2.59)6892.59(2.37--2.80)401                    nAT tabletsBaseline0.53(0.38--0.75)0.0069220.45(0.30--0.64)0.6901214Endline0.38(0.32--0.54)7020.46(0.40--0.54)473**Uganda**                    ACT tabletsBaseline5.85(3.86--6.42)0.0551483.86(0.39--5.42)0.266402Endline3.10(2.32--3.87)9071.86(1.55--2.32)867                    AMT tabletsBaseline8.48(7.71--9.26)\<0.0011489.26(7.71--9.95)267Endline19.35(19.35--19.35)62n/an/a0                    nAT tabletsBaseline0.72(0.47--0.72)\<0.0011480.47(0.43--0.60)\<0.0011074Endline1.63(1.08--2.44)9071.99(0.77--3.25)872**Zambia**                    ACT tabletsBaseline8.33(7.78--9.37)0.0016367.29(2.60--8.75)0.385109Endline6.75(3.91--7.83)3863.91(0.00--5.87)91                    AMT tabletsBaseline5.42(5.42--6.67)\<0.001222n/an/a0Endline4.89(4.70--4.89)109n/an/a0                    nAT tabletsBaseline0.52(0.46--0.62)0.0117950.50(0.40--0.62)0.616264Endline0.49(0.39--0.49)4400.49(0.39--0.59)243[^2]

Data were provided by ACTwatch, a research project led by Population Services International in partnership with the London School of Hygiene & Tropical Medicine, and funded by the Bill & Melinda Gates Foundation and UKAID. Funding for this work was provided by the UK Economic and Social Research Council though the Secondary Data Analysis Initiative \[grant number ES/K00381X/1\]. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. BP, KH and CG are members of the LSHTM Malaria Centre (<http://malaria.lshtm.ac.uk/>). KH and CG are members of the Centre for Health Economics in London (<https://www.lshtm.ac.uk/research/centres-projects-groups/chil>).

Declarations of interest {#s0075}
========================

None.

Ethical statement {#s0080}
=================

This research was reviewed and approved by the Observational/Interventions Research Ethics Committee of the London School of Hygiene & Tropical Medicine (Reference no: 7420). The authors do not have any conflict of interest or any competing financial interests in relation to the work described. ACTwatch was funded by the Bill & Melinda Gates Foundation and UKAID. Funding for this work was provided by the UK Economic and Social Research Council though the Secondary Data Analysis Initiative \[grant number ES/K00381X/1\]. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

[^1]: \* Households not meeting eligibility criteria were not included in the household survey dataset

[^2]: This analysis is restricted to the price of antimalarial tablets as the most common dosage form used to treat uncomplicated malaria. At baseline, the median price of ACT faced by households was similar across urban and rural areas in Benin, but tended to be higher in urban areas in Nigeria, Uganda and Zambia. In all countries, the median price of ACT faced by households at baseline was many times higher than the price of nAT both in urban and rural areas; and when compared to the price of AMT, ACT tended to be cheaper in Uganda, more expensive in urban areas of Zambia, and comparable both in urban and rural areas of Benin and Nigeria.
